Granted Patent
B2
US 12,559,750 · App. 19/052,052 · Granted Feb 24, 2026
Methods and compositions for treatment of polycystic kidney disease
Inventors:
Denis Drygin (San Diego, CA); Garth A. Kinberger (San Diego, CA); Edmund Chun Yu Lee (San Diego, CA)
Assignee:
Regulus Therapeutics Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
Claims (16)
1 . A modified oligonucleotide having the structure:
or a pharmaceutically acceptable salt thereof.
2 . The modified oligonucleotide of claim 1 , wherein the pharmaceutically acceptable salt is a sodium salt.
3 . A modified oligonucleotide having the structure:
4 . A pharmaceutical composition comprising the modified oligonucleotide of claim 1 and a pharmaceutically acceptable diluent.
5 . The pharmaceutical composition of claim 4 , wherein the pharmaceutically acceptable diluent is an aqueous solution.
6 . The pharmaceutical composition of claim 5 , wherein the aqueous solution is a saline solution.
7 . A pharmaceutical composition comprising a modified oligonucleotide of claim 2 and a pharmaceutically acceptable diluent.
8 . The pharmaceutical composition of claim 7 , wherein the pharmaceutically acceptable diluent is an aqueous solution.
9 . The pharmaceutical composition of claim 8 , wherein the aqueous solution is a saline solution.
10 . A pharmaceutical composition comprising a modified oligonucleotide of claim 3 and a pharmaceutically acceptable diluent.
11 . The pharmaceutical composition of claim 10 , wherein the pharmaceutically acceptable diluent is an aqueous solution.
12 . The pharmaceutical composition of claim 11 , wherein the aqueous solution is a saline solution.
13 . A pharmaceutical composition comprising a modified oligonucleotide of claim 1 , which is a lyophilized composition.
14 . A pharmaceutical composition comprising a modified oligonucleotide of claim 2 , which is a lyophilized composition.
15 . A pharmaceutical composition comprising a modified oligonucleotide of claim 3 , which is a lyophilized composition.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 8, 2026
From: DRYGIN, DENIS; KINBERGER, GARTH A.; LEE, EDMUND CHUN YU
To: REGULUS THERAPEUTICS INC.
Reel/Frame 075209/0414 →
Continuity (4)
Continuation
PCTUS2022077766
· Oct 7, 2022
Provisional Application
63253933
· Oct 8, 2021
References Cited (83)
US 7683036B2
· Esau et al.
· 2010
[cited by applicant]
US 20080280940A1
· Farber et al.
· 2008
[cited by applicant]
US 20120088902A1
· Currie et al.
· 2012
[cited by applicant]
US 20130236453A1
· Croce et al.
· 2013
[cited by applicant]
US 20200392503A1
· Allerson et al.
· 2020
[cited by applicant]
US 20220025372A1
· Androsavich et al.
· 2022
[cited by applicant]
US 20220380767A1
· Allerson et al.
· 2022
[cited by applicant]
US 20230109466A1
· Allerson
· 2023
[cited by applicant]
US 20240141350A1
· Allerson et al.
· 2024
[cited by applicant]
CN 101300008A
· 2008
[cited by applicant]
EP 1777301A2
· 2007
[cited by applicant]
JP 2007529459A
· 2007
[cited by applicant]
WO 2005089731A2
· 2005
[cited by applicant]
WO 2005103298A2
· 2005
[cited by applicant]
WO 2006020768A2
· 2006
[cited by applicant]
WO 2007112753A2
· 2007
[cited by applicant]
WO 2007126150A1
· 2007
[cited by applicant]
WO 2008042973A2
· 2008
[cited by applicant]
WO 2008091703A2
· 2008
[cited by applicant]
WO 2008131191A2
· 2008
[cited by applicant]
WO 2008151639A2
· 2008
[cited by applicant]
WO 2009043353A2
· 2009
[cited by applicant]
WO 2009109665A1
· 2009
[cited by applicant]
WO 2011060100A1
· 2011
[cited by applicant]
WO 2013165320A1
· 2013
[cited by applicant]
WO 2014179446A2
· 2014
[cited by applicant]
WO 2015061684A1
· 2015
[cited by applicant]
WO 2015123449A2
· 2015
[cited by applicant]
WO 2017035319A1
· 2017
[cited by applicant]
WO 2018047148A1
· 2018
[cited by applicant]
WO 2018106566A1
· 2018
[cited by applicant]
WO 2018106568A1
· 2018
[cited by applicant]
WO 2021153762A1
· 2021
[cited by applicant]
WO 2023060237A1
· 2023
[cited by applicant]
WO 2023060238A2
· 2023
[cited by applicant]
WO 2024215846A1
· 2024
[cited by applicant]
Abraham et al., “Nucleobase analogs for degenerate hybridization devised through conformational pairing analysis”, Biotechniques 43(5):617-624 (2007).
[cited by applicant]
Anonymous “Securities and Exchange Commission Form 8-K,” Retrieved from the internet: http://pdf.secdatabase.com/19/0001193125-21-169262.pdf, pp. 1-34 (2021).
[cited by applicant]
Carney, “MicroRNA-17: A New Drug Target for ADPKD,” Nature Reviews Nephrology, Mar. 6, 2017, 1 page.
[cited by applicant]
Davis et al., “Improved targeting of miRNA with antisense oligonucleotides,” Nucleic Acids Res. 34(8):2294-304 (2006).
[cited by applicant]
Hajarnis et al., “Chapter 13: MicroRNAs and Polycystic Kidney Disease,” Brisbane: Codon Publications, Nov. 2015, 13 pages.
[cited by applicant]
Hajarnis et al., “MicroRNA-17 Family Promotes Polycystic Kidney Disease Progression Through Modulation of Mitochondrial Metabolism,” Nature Communications, 2017, 8:1-14.
[cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2022/077766, mailed Feb. 6, 2023, 14 pages.
[cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2022/077767, mailed Mar. 27, 2023, 25 pages.
[cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2024/024006, mailed Jun. 27, 2024, 19 pages.
[cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2017/064432, dated Apr. 4, 2018, 20 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority in International Application No. PCT/US2017/064428, dated Mar. 26, 2018, 17 pages.
[cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2016/048603, dated Nov. 30, 2016, 17 pages.
[cited by applicant]
Kamiya et al., “Introduction of 2,6-Diaminopurines into Serinol Nucleic Acid Improves Anti-miRNA Performance,” ChemBioChem 18(19):1917-1922 (2017).
[cited by applicant]
Koizumi, “Nucleic Acids Therapeutics Using Chemical Modified Oligonucleotides,” Medchem News, 2015, 25(2):103-108.
[cited by applicant]
Kurschat et al., “An Approach to Cystic Kidney Diseases: the Clinician's View,” Nature Reviews, 2014, 10:687-699.
[cited by applicant]
Lakhia et al., “MicroRNA-21 Aggravates Cyst Growth in a Model of Polycystic Kidney Disease,” J Am Soc Nephrol, 2015, 27:1-12.
[cited by applicant]
Lee et al., “Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease,” Nature Communications 10(1)1-14 (2019).
[cited by applicant]
Lee et al., “Discovery of Next-generation Anti-miR-17 Oligonucleotide RGLS8429 for Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD),” Regulus presentation, 1 page (2022).
[cited by applicant]
Lee, “Discovery of Next-generation Anti-miR-17 Oligonucleotide RGLS8429 for Treatment of ADPKD,” Regulus presentation, Federation of American Society of Experimental Biology (FASEB), The Polycystic Kidney Disease Confer…
[cited by applicant]
Liu et al., “2-aminopurine probe in combination with catalyzed hairpin assembly signal amplification for simple and sensitive detection of microRNA”, Talanta, Elsevier vol. 174, pp. 336-340 (2017), Abstract Only, 1 page.
[cited by applicant]
Matsubara et al., “Apoptosis Induction by Antisense Oligonucleotides Against miR-17-5p and miR-20a in Lung Cancers Overexpressing miR-17-92,” Oncogene, 2007, 26(41):6099-6105.
[cited by applicant]
Murphy et al., “Silencing of the miR-17 92 Cluster Family Inhibits Medulloblastoma Progression,” Cancer Research 73(23):7068-7078 (2013).
[cited by applicant]
NIH Grant 1R01DK102572-01A1, “MicroRNAs: New Regulators of Disease Progression in Polycystic Kidney Disease,” Awarded May 11, 2015, downloaded Feb. 20, 2018, 2 pages.
[cited by applicant]
NIH Grant 1R03DK099568-01, “Mirna Based Therapeutics in Polycystic Kidney Disease,” Awarded Jul. 19, 2013, downloaded Feb. 20, 2018, 2 pages.
[cited by applicant]
NIH Grant 5R01DK102572-02, “MicroRNAs: New Regulators of Disease Progression in Polycystic Kidney Disease,” Awarded May 2, 2016, downloaded Feb. 20, 2018, 2 pages.
[cited by applicant]
NIH Grant 5R01DK102572-03, “MicroRNAs: New Regulators of Disease Progression in Polycystic Kidney Disease,” Awarded May 1, 2017, downloaded Feb. 20, 2018, 2 pages.
[cited by applicant]
NIH Grant 5R03DK099568-02, “Mirna-Based Therapeutics in Polycystic Kidney Disease,” Awarded Jun. 14, 2014, downloaded Feb. 20, 2018, 2 pages.
[cited by applicant]
Noureddine, et al., “MicroRNAs and Polycystic Kidney Disease,” Drug Discovery Today, Disease Models, 2013, 10(3):e137-e143.
[cited by applicant]
Patel et al., “Inactivation of miR-17˜92 Suppresses Cyst Growth in Genetic Models of ADPKD,” Presentation, Kidney Week, Oct. 2014, 17 pages.
[cited by applicant]
Patel et al., “miR-17˜92 miRNA Cluster Promotes Kidney Cyst Growth in Polycystic Kidney Disease,” PNAS, 2013, 110(26):10765-10770.
[cited by applicant]
Presentation by Lee, “Discovery of the next-generation anti-miR-17 oligonucleotide RGLS8429 for treatment of ADPKD,” Regulus R&D Day, 11 pages (2023).
[cited by applicant]
Serva et al., “miR-17-5p Regulates Endocytic Trafficking Through Targeting TBC1D2/Armus,” PLOS One, 2012, 7(12): e52555, 1-15.
[cited by applicant]
Seth et al., “Short Antisense Oligonucleotides with Novel 2′-4′ Conformationaly Restricted Nucleoside Analogues Show Improved Potency without Increased Toxicity in Animals,” J. Med. Chem. 52:10-13 (2009).
[cited by applicant]
Stenvang et al., “Inhibition of microRNA function by antimiR oligonucleotides,” Silence 3(1): 1-17 (2012).
[cited by applicant]
Sun et al., “MicroRNA-17 Post-Transcriptionally Regulates Polycystic Kidney Disease-2 Gene and Promotes Cell Proliferation,” Mol Biol Rep, 2010, 37(6):2951-2958.
[cited by applicant]
Tran et al., “The RNA-Binding Protein Bicaudal C Regulates Polycystin 2 in the Kidney by Antagonizing miR-17 Activity,” Development, 2010, 137(7):1107-1116.
[cited by applicant]
Yheskel et al., “Anti-microRNA screen uncovers miR-17 family within miR-17˜92 cluster as the primary driver of kidney cyst growth,” Scientific Reports 9:1920, 11 pages (2019).
[cited by applicant]
Yheskel et al., “Therapeutic microRNAs in Polycystic Kidney Disease,” Current Opin Nephrol Hypertens, 2017, 26: 1-8.
[cited by applicant]
U.S. Appl. No. 19/019,923, filed Jan. 14, 2025.
[cited by applicant]
U.S. Appl. No. 18/693,783, filed Mar. 20, 2024.
[cited by applicant]
Regulus press release entitled “Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment of Autosomal Dominate Polycystic Kidney Disease,” Oct. 12, 2021, 3 pag…
[cited by applicant]
Valencia et al., “Deciphering and overcoming off-target AMPAR inhibition of anti-miR oligonucleotide RGLS4326,” poster presented at the 2024 meeting of the Oligonucleotide Therapeutics Society (Oct. 6-9, 2024).
[cited by applicant]